mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

BRAF inhibitors (BRAFi) and the combination therapy of BRAF and MEK inhibitors (MEKi) were recently approved for therapy of metastatic melanomas harbouring the oncogenic BRAFV600 mutation. Although these therapies have shown pronounced therapeutic efficacy, the limited durability of the response ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Gongda, Kohler, Reto, Tang, Fengyuan, Hynx, Debby, Wang, Yuhua, Orso, Francesca, Prêtre, Vincent, Ritschard, Reto, Hirschmann, Petra, Cron, Peter, Roloff, Tim, Dummer, Reinhard, Mandalà, Mario, Bichet, Sandrine, Genoud, Christel, Meyer, Alexandra G., Muraro, Manuele G., Spagnoli, Giulio C., Taverna, Daniela, Rüegg, Curzio, Merghoub, Taha, Massi, Daniela, Tang, Huifang, Levesque, Mitchell P., Dirnhofer, Stephan, Zippelius, Alfred, Hemmings, Brian A., Wicki, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642473/
https://www.ncbi.nlm.nih.gov/pubmed/29050198
http://dx.doi.org/10.18632/oncotarget.18213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642473/
https://www.ncbi.nlm.nih.gov/pubmed/29050198
http://dx.doi.org/10.18632/oncotarget.18213

Ejemplares similares